Literature DB >> 19287132

Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.

Silvana Capalbo, Giuseppina Spinosa, Maria Grazia Franzese, Gaetano Palumbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19287132     DOI： 10.1159/000209206

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  9 in total

1.  Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.

Authors:  Takamasa Nishiuchi; Yuichi Okutani; Toshikazu Fujita; Kazuya Yoshida; Hiroaki Ohnishi; Reiji Haba
Journal:  Int J Hematol       Date:  2010-02-04       Impact factor: 2.490

Review 2.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

3.  Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.

Authors:  Minoru Kojima; Shinichiro Machida; Ai Sato; Mitsuki Miyamoto; Makiko Moriuchi; Yoshiaki Ohbayashi; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-10-26       Impact factor: 2.490

4.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

5.  Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.

Authors:  Jong Wook Lee; Sung-Soo Yoon; Zhi Xiang Shen; Arnold Ganser; Hui-Chi Hsu; Ali El-Ali; Dany Habr; Nicolas Martin; John B Porter
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

7.  Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.

Authors:  Mathieu Meunier; Sarah Ancelet; Christine Lefebvre; Josiane Arnaud; Catherine Garrel; Mylène Pezet; Yan Wang; Patrice Faure; Gautier Szymanski; Nicolas Duployez; Claude Preudhomme; Denis Biard; Benoit Polack; Jean-Yves Cahn; Jean Marc Moulis; Sophie Park
Journal:  Oncotarget       Date:  2017-11-06

Review 8.  Myelodysplastic Syndromes and Iron Chelation Therapy.

Authors:  Emanuele Angelucci; Silvana Anna Maria Urru; Federica Pilo; Alberto Piperno
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-03-01       Impact factor: 2.576

9.  Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Authors:  Harpreet Kochhar; Chantal S Leger; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2015-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.